Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.

Abstract

Adoptive immunotherapy in the T cell landscape exhibits efficacy in cancer treatment. Over the past few decades, genetically modified T cells, particularly chimeric antigen receptor T cells, have enabled remarkable strides in the treatment of hematological malignancies. Besides, extensive exploration of multiple antigens for the treatment of solid tumors has led to clinical interest in the potential of T cells expressing the engineered T cell receptor (TCR). TCR-T cells possess the capacity to recognize intracellular antigen families and maintain the intrinsic properties of TCRs in terms of affinity to target epitopes and signal transduction. Recent research has provided critical insight into their capability and therapeutic targets for multiple refractory solid tumors, but also exposes some challenges for durable efficacy. In this review, we describe the screening and identification of available tumor antigens, and the acquisition and optimization of TCRs for TCR-T cell therapy. Furthermore, we summarize the complete flow from  laboratory to clinical applications of TCR-T cells. Last, we emerge future prospects for improving therapeutic efficacy in cancer world with combination therapies or TCR-T derived products. In conclusion, this review depicts our current understanding of TCR-T cell therapy in solid neoplasms, and provides new perspectives for expanding its clinical applications and improving therapeutic efficacy.

• Authors: Weihuan Shao, Yiran Yao, Ludi Yang, Xiaoran Li, Tongxin Ge, Yue Zheng, Qiuyi Zhu, Shengfang Ge, Xiang Gu, Renbing Jia, Xin Song, Ai Zhuang
• Journal: Experimental hematology & oncology (Exp Hematol Oncol) Vol. 13 Issue 1 Pg. 37 (Apr 03 2024) ISSN: 2162-3619 [Print] England
• PMID: 38570883 (Publication Type: Journal Article, Review)
• Copyright: © 2024. The Author(s).